Guoshuai Cao
Overview
Explore the profile of Guoshuai Cao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li J, Wang X, Cao G, Wu Y, Cheng M, Chen Y, et al.
Cancer Lett
. 2024 Oct;
605:217305.
PMID: 39424259
NKG2 family members have emerged as promising targets in tumor immunotherapy. CD94 can dimerize with both inhibitory and activating NKG2 proteins, while the overall effect and value of targeting CD94...
2.
Huang X, Meng L, Cao G, Prominski A, Hu Y, Yang C, et al.
Nat Methods
. 2024 Feb;
21(5):857-867.
PMID: 38374262
Studies using antigen-presenting systems at the single-cell and ensemble levels can provide complementary insights into T-cell signaling and activation. Although crucial for advancing basic immunology and immunotherapy, there is a...
3.
Pan T, Cao G, Tang E, Zhao Y, Penaloza-MacMaster P, Fang Y, et al.
Front Genet
. 2023 Mar;
14:1105673.
PMID: 36992700
Within the inflammatory immune response to viral infection, the distribution and cell type-specific profiles of immune cell populations and the immune-mediated viral clearance pathways vary according to the specific virus....
4.
Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35580929
Background: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8 T cells. Paradoxically, continuous T cell receptor (TCR) stimulation...
5.
Cao G, Yang S, Cao J, Tan Z, Wu L, Dong F, et al.
Oxid Med Cell Longev
. 2022 Jan;
2022:2166817.
PMID: 35069969
Intervertebral disc degeneration is a very common type of degenerative disease causing severe socioeconomic impact, as well as a major cause of discogenic low back pain and herniated discs, placing...
6.
Pan T, Cao G, Tang E, Zhao Y, Penaloza-MacMaster P, Fang Y, et al.
bioRxiv
. 2022 Jan;
PMID: 35043114
Highlights: COVID-19 and HIV-1 patients show disease-specific inflammatory immune signatures COVID-19 patients show more productive humoral responses than HIV-1 patients SARS-CoV-2 elicits more enriched IFN-I signaling relative to HIV-IDivergent, impaired...
7.
Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y, et al.
Cell Mol Immunol
. 2022 Jan;
19(2):192-209.
PMID: 35043005
Cytokines exert powerful immunomodulatory effects that are critical to physiology and pathology in humans. The application of natural cytokines in clinical studies has not been clearly established, and there are...
8.
Hu Y, Cao G, Chen X, Huang X, Asby N, Ankenbruck N, et al.
Matter
. 2021 Dec;
4(12):3917-3940.
PMID: 34901832
Although chimeric antigen receptor (CAR) T-cell therapy has transformed cancer treatment, high-quality and universal CAR-staining reagents are urgently required to manufacture CAR T cells, predict therapy response, decipher CAR biology,...
9.
Cao G, Cheng Y, Zheng X, Wei H, Tian Z, Sun R, et al.
Cancer Commun (Lond)
. 2021 Jul;
41(1):51-61.
PMID: 34236140
Background: The interaction between activating receptor NKp30 and its major tumor ligand B7-H6 is important for NK cell-mediated tumor rejection. However, the regulation of B7-H6 by tumor therapeutics remains largely...
10.
Li Y, Zhang Y, Cao G, Zheng X, Sun C, Wei H, et al.
J Hematol Oncol
. 2021 Jun;
14(1):100.
PMID: 34174928
Background: Although checkpoint-based immunotherapy has shown exciting results in the treatment of tumors, around 70% of patients have experienced unresponsiveness. PVRIG is a recently identified immune checkpoint receptor and blockade...